Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Fatal Familial Cholesterol Disease Overlooked

By LabMedica International staff writers
Posted on 04 Nov 2013
Familial hypercholesterolemia (FH) is a common genetic cause of premature coronary heart disease (CHD), namely myocardial infarction and angina pectoris, due to lifelong elevated plasma low-density lipoprotein (LDL) cholesterol levels.

Owing to severe underdiagnoses and under treatment of FH, there is an urgent worldwide need for diagnostic screening together with early and aggressive treatment of this extremely high-risk condition, which if once diagnosed, can readily be treated with cholesterol-lowering medication to attenuate development of atherosclerosis and to prevent CHD.

Clinical biochemists at the University of Copenhagen (Denmark) with their international collaborators, found that for a theoretical estimated prevalence of 1 in 500 for heterozygous FH, less than 1% are diagnosed in most countries. More...
Recently, direct screening in a Northern European general population diagnosed approximately 1 in 200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD.

Based on prevalence between 1 in 500 and 1 in 200, between 14 and 34 million individuals worldwide have FH. The investigators recommend that children, adults, and families should be screened for FH if a person or family member presents with FH, a plasma cholesterol level in an adult of equal to or greater than 8 mmol/L (≥ 310 mg/dL) or a child with equal to or greater than 6 mmol/L (≥ 230 mg/dL), premature CHD, tendon xanthomas, or sudden premature cardiac death. The FH condition can be confirmed with a gene test.

In FH, low-density lipoprotein cholesterol targets are less than 3.5 mmol/L (<135 mg/dL) for children, and less than 2.5 mmol/L (<100 mg/dL) for adults, and less than 1.8 mmol/L (<70 mg/dL) for adults with known CHD or diabetes. M. John Chapman, PhD, DSc, a professor at the Pitié-Salpetriere University Hospital (Paris, France) and a senior author of the study said, “It is surprising and sad that even rich countries with highly developed health systems fail to help these people. It is not a question of economic resources, as the disease is easy to diagnose and inexpensive to treat.” The study was published online on August 15, 2013, in the European Heart Journal.

Related Links:

University of Copenhagen
Pitié-Salpetriere University Hospital



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.